4th Issue – The Myths We Inject With
ON THE TABLE
- 🗺️ Where VOs Actually Happen
- 🧮 That IU Count Is A Lie
- 🫥 Why Hyaluronidase Ghosts You Mid-Emergency
- 🏦 Your Valuation Is Watching
📓 FIELD NOTES
Fourteen injectors circled around him like apostles.
Apollo had the influencer following, the KOL status, and the weekly training schedule. He injected the model with practiced ease and told the room, matter-of-factly,
“Vascular occlusions happen quick. You’ll know right away.”
Fourteen injectors nodded.
He wasn’t lying. He was teaching what he believed. What he believed just hadn’t been updated in a while.Neither malicious nor reckless, he was confidently and consequentially wrong.
That’s the most dangerous place in this industry; confidence built on assumptions the literature has already dismantled.
That’s what this issue is about.
🪡 THE NEEDLEPOINT
- Galderma Gets the Temple – FDA cleared first temple filler, Restylane Countour. Galderma collects anatomical real estate while the rest fight over cheeks and lips.
- East Moves First. Again. – In South Korea, Medyox launches NUVIJU, the world’s first cholic acid fat dissolver. Less swelling, body-matched pH, no benzyl alcohol. Kybella’s best nightmare.
- Crown Gets Cheeks – Revance launches RHA Dynamic Volume for mid-face. The rebrand chapter writes itself faster than anyone expected.
- Moxie Raises $25M – Series C for clinical-grade ops infrastructure for indue practices. Those not acquired get equipped.
- Your Valuation is Watching – A 2026 medspa M&A brief calls adverse event documentation a landmine that can kill deals or compress multiples overnight.
🧠 ONE NEEDLE, ONE STAT
59.2%
The share of documented filler vascular events that resulted in necrosis at a clinic built specifically to prevent that outcome.
If that’s what complication specialists get…
…what are the rest of us getting?
🔦 THE SPOTLIGHT
The Myths We Inject With
The industry has a safety culture built on the wrong assumptions.
Slow injection speed, avoid danger zones, inject small deposits, and should disaster or dissatisfaction strike – hyaluronidase to the rescue.They’re in training curricula, manufacturer materials, and the private groups where injectors go for real answers.
The published literature says something different.
…what are the rest of us getting?
🔦 THE SPOTLIGHT
The Myths We Inject With
The industry has a safety culture built on the wrong assumptions.
Slow injection speed, avoid danger zones, inject small deposits, and should disaster or dissatisfaction strike – hyaluronidase to the rescue.They’re in training curricula, manufacturer materials, and the private groups where injectors go for real answers.
The published literature says something different.
…what are the rest of us getting?